EU post-market obligations for drugs and biologics
What EU law requires of marketing authorisation holders after authorisation, from adverse reaction reporting and PSURs to additional monitoring.
4 posts
What EU law requires of marketing authorisation holders after authorisation, from adverse reaction reporting and PSURs to additional monitoring.
How FDA post-approval duties work for drugs and biologics, covering adverse experience reports, annual and distribution reports, changes and supply notices.
How Regulation (EU) 2017/745 governs post-market surveillance, PSURs, vigilance reporting deadlines and field safety corrective actions for medical devices.
How 21 CFR Parts 803, 806 and 822 govern adverse event reporting, corrections and removals and ordered postmarket surveillance for US devices.